Company profile: Emergent BioSolutions
1.1 - Company Overview
Company description
- Provider of medical countermeasures for biological and chemical threats, developing, manufacturing, and delivering products including NARCAN® Nasal Spray to rapidly reverse opioid overdose; BioThrax® and CYFENDUS™ anthrax vaccines; ACAM2000® smallpox vaccine; TEMBEXA® antiviral for smallpox; and EbangaTM therapeutic antibody for Ebola virus infection.
Products and services
- ACAM2000®: A live vaccinia virus vaccine engineered to immunize against smallpox disease by initiating protective immune response
- Live-virus formulation for smallpox immunization
- BioThrax®: An FDA-licensed anthrax vaccine delivering active immunization against anthrax disease
- FDA-licensed biologic for anthrax prevention
- CYFENDUS™: An anthrax vaccine adsorbed with adjuvant for enhanced immunization against anthrax
- Adjuvanted vaccine formulation supporting enhanced immunization.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Emergent BioSolutions
Specific Diagnostics
HQ: United States
Website
- Description: Provider of patented medical device technology leveraging a low-cost small molecule sensor to enable diagnostic products that simplify workflow and speed time-to-answer at a low cost.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Specific Diagnostics company profile →
DeepUll
HQ: Spain
Website
- Description: Provider of a biotech diagnostic system for early-stage sepsis that rapidly identifies pathogens and delivers an antibiogram within hours, leveraging patient immunological and functional data.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full DeepUll company profile →
Cerexa
HQ: United States
Website
- Description: Provider of novel anti-infective therapies for serious and life-threatening infections; develops a portfolio of treatments including Ceftaroline Acetate/Ceftaroline, an injectable cephalosporin used for bacterial infections.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cerexa company profile →
ITS Innovation
HQ: United Kingdom
Website
- Description: Provider of synthetic vaccines for mutating viruses using a T-cell vaccine platform that targets conserved viral antigens to direct immune responses, and of pemvidutide, a GLP-1/glucagon dual receptor agonist for obesity and MASH, designed to reduce body weight, liver fat, serum lipids, and address liver fat and fibrosis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ITS Innovation company profile →
Protez Pharmaceuticals
HQ: United States
Website
- Description: Provider of differentiated intravenous and oral small molecule antibiotics for difficult-to-treat hospital-based infections, addressing bacterial resistant and chronic or recurrent infections; discovers, develops, and commercializes antibiotic therapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Protez Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Emergent BioSolutions
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Emergent BioSolutions
2.2 - Growth funds investing in similar companies to Emergent BioSolutions
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Emergent BioSolutions
4.2 - Public trading comparable groups for Emergent BioSolutions
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →